Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently weighed in on MRNS. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research report on Monday, September 23rd. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Finally, TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $0.54 on Friday. The firm has a market capitalization of $29.69 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $11.26. The business’s fifty day moving average price is $0.33 and its two-hundred day moving average price is $1.05.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds have recently modified their holdings of MRNS. abrdn plc lifted its holdings in shares of Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after buying an additional 1,578,329 shares during the period. Suvretta Capital Management LLC lifted its holdings in Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after acquiring an additional 1,253,901 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of Marinus Pharmaceuticals by 409.4% in the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 817,050 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth approximately $813,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.